Put your brand in front of 28,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏭 Abbott cuts loose $8.5 billion in formula and shakes

Abbott will spin its global nutrition business into a separate public company, handing shareholders stock in both. The unit carries about $8.5 billion in annual sales, 16,000 employees and 14 plants, with Ensure, PediaSure, Glucerna and Similac. It should stand alone by the end of 2027. Abbott cut full-year guidance the same morning, trimming comparable sales growth to 6% and EPS to $5.50 to $5.55. The medtech core gets the attention now, and the scrutiny with it.

MassDevice

2.🤝 EQT is taking Qiagen private at €10.8 billion

Qiagen’s boards unanimously backed an all-cash offer from EQT at €46.50 a share, a 40% premium to its July close, valuing the diagnostics company at about €10.8 billion including debt. ADIA and CPP Investments are co-investing. Closing is expected mid-2027, with Frankfurt and NYSE delistings to follow. Sample prep and molecular testing are steady, unglamorous businesses that private capital can hold through a rebuild. Expect more of this where public multiples have stopped rewarding the work.

QIAGEN

3. 🧩 The year’s biggest orthopedics deal died over who would run it

Merger talks between Smith+Nephew and J&J’s orthopedics business collapsed weeks before a mid-October close, according to people familiar with them. J&J shareholders would have held 50.1% of a company roughly twice Smith+Nephew’s £9.4 billion market value, with the hip and knee unit alone valued near $22 billion. J&J wanted Namal Nawana, Smith+Nephew’s CEO until 2019, to lead it; Smith+Nephew wanted to keep Deepak Nath. Neither side has confirmed the talks, and Smith+Nephew’s growth problem is still there for whoever comes next.

MD+DI

4. 🔒 Quest tells the SEC that patient records were taken

Quest Diagnostics disclosed a cyberattack in an 8-K filing, saying unauthorized access touched certain patient records in Quanum, the ordering and billing platform it says about half a million clinicians use across North America. Quest has not said how many patients are affected, what data was taken, or when the intrusion began. Law enforcement is involved. The exposure sits in the ordering layer, not the lab, and that layer is what most diagnostics companies now rent from someone else.

TechCrunch

5. 🩹 Solventum gets to sell the $900 million acquisition as one system

FDA cleared Solventum’s Restrata resorbable matrix for use with its V.A.C. negative pressure wound therapy, including the Ulta unit and Granufoam dressings. Restrata came with Acera Surgical, bought for $900 million and closed in late 2025. The company argues Restrata’s slower absorption suits seven-day peel-and-place dressings where collagen products break down early. This is what an acquisition should look like two years on: one label, one call point, one reason the premium made sense.

MassDevice

6. 🇯🇵 Japan’s regulator writes down what it would need to approve a generative AI device

PMDA published English review points for generative AI in medical devices, acknowledging no adequate framework exists for bounding or judging outputs. It leans on a total life cycle approach: premarket evidence may hold if gathered under representative conditions, provided that status is maintained after launch and incidents get caught. PMDA has approved none of these devices yet. Three regulators have now said much the same thing in three documents, which matters to anyone building one file and submitting it three times.

RAPS

7. 🧠 Founders Fund and OpenAI’s venture arm put $45 million into a brain tumor implant

Coherence Neuro raised $45 million co-led by Founders Fund and the OpenAI Startup Fund, with Lux Capital, 8VC and Ahren joining. Its SOMA system reads electrical signals tied to a tumor and uses them to steer stimulation, pairing a wireless implant with an over-ear power and data unit. A cortical probe entered first-in-human use in June at Royal Melbourne Hospital. Nothing is approved anywhere, the biomarkers are validated in mice, and a chronic glioblastoma trial is next.

Health Tech World

8. 👂 Med-El’s new cochlear implant has no outside part at all

Med-El launched TICI Unico in several European markets, calling it the first fully implantable cochlear implant. Microphone included, everything sits under the skin, so recipients hear while sleeping, swimming and charging. The battery is expected to last 15 years or more, and a daily external charger looks like a conventional processor. It carries a CE mark and no FDA approval. Austria built the thing device marketing has promised for years: the implant nobody can see.

MD+DI

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Intuitive will pay $450 million to settle the hospital repair case. On the same call, it said it will extend the life of the instruments the case was about.

Intuitive disclosed on October 20 that it had agreed to settle In re Da Vinci Surgical Robot Antitrust Litigation for a one-time payment of $450 million plus what the company calls mutually agreed injunctive relief, reached after an October mediation and carrying no admission of liability. The charge landed in third-quarter selling, general and administrative expenses: $347 million net of tax, 99 cents a share, cutting GAAP net income to $523 million on revenue of $3.05 billion. The settlement still needs preliminary and final court approval, and CFO Jamie Samath told analysts the company does not expect a decision until next year.

The case was never about robots. Entities that bought da Vinci service and EndoWrist instruments in the United States between May 21, 2017 and the end of 2021 — the class Judge Araceli Martínez-Olguín certified in March 2025, under both the damages and the injunctive-relief provisions of Rule 23 — alleged that Intuitive tied the machine to its own service contract, barred independent repair and self-servicing, and capped each EndoWrist at roughly ten uses by means of a counter inside the instrument, forcing replacement purchases it controlled. Tying, exclusive dealing, monopolization. The district court had already held in March 2024 that the robot and the instruments are separate products, then vacated its own findings on Intuitive’s power in the instrument aftermarket four months later, reading the Ninth Circuit’s Epic Games decision to require that a single-brand aftermarket’s restrictions be unknown to buyers at the time of purchase. Intuitive’s restrictions were in the signed contracts.

Then that reading collapsed. On August 13 the Ninth Circuit reversed a judgment in Intuitive’s favor in a parallel case brought by Surgical Instrument Service, the company that marketed a counter-reset service for used EndoWrists. Writing for the panel, Judge Lucy Koh held that the Kodak and Epic lock-in factors apply only where a plaintiff cannot show the defendant has power in the foremarket. SIS put in evidence that Intuitive held more than 99 percent of the US market for minimally invasive surgical robots and all of the EndoWrist aftermarket, which makes it an ordinary foremarket-to-aftermarket tying case with no lock-in showing required. The error, the court said, infected every claim, and a jury could also find Intuitive’s process for approving third-party products and services illusory. That is the rule the Federal Trade Commission had asked the court to adopt a year earlier, in a brief supporting neither party: the lock-in factors “have no role to play when there is no meaningful competition in the foremarket.”

So the class settles and the doctrine hardens. SIS goes back to the district court with live claims and an appellate rule that makes the aftermarket theory materially easier to run against any manufacturer with a dominant installed base. Intuitive had 12,094 da Vinci systems in the field at the end of September.

Which is the context for the other thing management said on that call. Samath told analysts the company will extend the useful lives of a subset of core EndoWrist instruments beginning in the first half of 2027, pending a 510(k) that is in process, and that this plus a China price reduction will lower da Vinci instrument and accessory revenue per procedure by roughly 3 to 5 percent on a mix-constant basis. He framed it as a deliberate choice to broaden adoption in high-volume benign procedures where cost is a barrier.

Read it that way and it is a growth decision. Read the docket and it is the use counter, loosened, in the same quarter the company agreed to pay $450 million to end a case about the use counter. Intuitive has not said the two are connected, the injunctive terms are not public, and CEO David Rosa described the agreement as a no-fault settlement that “provides certainty for both our customers and Intuitive.”

The transferable part is not the money. It is that an aftermarket built on a consumable limit, a captive service contract and a company-run approval process for third parties is now a litigable structure rather than a commercial one, and the Ninth Circuit just lowered the cost of testing it. Any device company whose plan assumes the blades earn more than the handle should price that in before someone else does it for them.

Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏭 Steris pays $2.1B for positioning pads and turnover kits

Steris will buy Xodus Medical for $2.1 billion, with up to $150 million more in earnout through 2028. About $300 million in tax benefits takes the net to roughly $1.8 billion against an estimated $245 million of 2026 revenue. Xodus makes patient positioning pads, bed straps, OR turnover kits and laparoscopic defogging hardware. Steris is paying a growth multiple for consumables, not technology. It is the clearest signal yet that recurring hospital spend is the asset class everyone wants.

MassDevice

2.📉 J&J’s medtech engine downshifts again

MedTech sales hit $8.64 billion in Q3, up 2.5% year over year, after growing above 7% in both Q1 2026 and Q4 2025. Surgery fell 0.6%. Abiomed slid 2.3% to $412 million, its second straight decline, which Tim Schmid pinned on lower Impella volume after an unfavorable UK study and called a temporary headwind. Two quarters is a pattern, not a blip, and the PROTECT IV readout that would settle the argument does not arrive until next year.

MedTech Dive

3. 🤖 The AMA draws a line around clinical AI agents

The AMA published a governance framework for agentic AI taking on clinical functions, built on four questions: what function the AI performs, what evidence shows it can, what it should be permitted to do and under what conditions, and who owns the risk when it fails. The stated principle is that clinical authority is earned through evidence and kept through demonstrated performance. Device makers shipping autonomous features should read this as the liability conversation starting without them.

American Medical Association

4. 🧪 Labcorp buys the rest of BioReference

Labcorp will pay Opko Health $722 million upfront plus up to $150 million tied to 4Kscore revenue for BioReference’s clinical and women’s health testing, its correctional-facility urology services and more than 80 patient service centers. Labcorp expects roughly $250 million of revenue in the first year after closing. This finishes the job it started in March 2025 with BioReference’s oncology assets, and it buys national distribution for a prostate test that never escaped New York and New Jersey.

MedTech Dive

5. 🩻 Siemens walks out of general ultrasound

As of October 12, Siemens Healthineers no longer sells its Acuson Sequoia, Redwood, Juniper or Maple general imaging ultrasound systems. It will keep servicing the installed base and will sell only procedural platforms: Acuson Origin, the P500 intracardiac echo system and Freestyle, aimed at electrophysiologists and interventional cardiologists. Trading a commoditized imaging category for catheter-adjacent margin is a coherent bet. It also hands general ultrasound to its remaining rivals and the handheld entrants without a fight.

AuntMinnie

6. 💉 twiist clears for type 2, and the trial population is the story

FDA cleared Sequel Med Tech’s twiist automated insulin delivery system for adults with insulin-treated type 2 diabetes, roughly 5.5 million more Americans. In the 307-patient twiist-T2D trial, A1c fell 0.7% from a baseline of 8.1%, time in range rose 16 points to 73%, and no severe hypoglycemia was reported. Only 11% of participants had ever counted carbohydrates. Pumps have spent two decades selling to the motivated minority. This is the first credible claim on everyone else.

Sequel Med Tech

7. ⚠️ Edwards pulls delivery lots ten months into a launch

FDA issued an early alert on October 15 covering four lots of Edwards Lifesciences’ Commander M delivery system, used to place the Sapien M3 mitral valve, after three reports of balloons bursting during inflation. One death and one serious injury were reported as of October 5, across fewer than 200 affected systems. Sapien M3 was approved in December 2025 for patients unsuitable for surgery, which is precisely the population least able to absorb a bailout procedure.

TCTMD

8. 🌐 China opens comment on export curbs covering AI models

Beijing’s commerce and science ministries proposed adding 40 technologies to China’s export control catalog, with comment open until November 15. Twenty-three are AI items, including large models, intelligent agents and compute clusters. Five are biomedicine, covering cell and gene therapy and nucleic acid drugs. No device categories are named. The exposure is indirect but real: any device software built on a Chinese open-weight model now carries a policy risk line in its regulatory file.

Xinhua

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

FDA’s new Olympus warning letter covers six plants in three countries. Two of them are plants the agency already wrote to.

The letter is dated October 7. Olympus disclosed it on October 13, and named the sites: Olympus Medical Systems in Hachioji and Hinode, Aomori Olympus, Shirakawa Olympus, Olympus Winter & IBE in Hamburg, and Gyrus ACMI in Brooklyn Park, Minnesota. Japan, Germany and the US, all from inspections that closed in late 2025. The company says the findings “primarily concern aspects of the company’s quality management system and related processes,” and that the letter challenges the adequacy of its responses to the Form 483 observations those inspections produced.

Read that last part slowly. A warning letter that disputes a company’s 483 responses is not a letter about what inspectors found. It is a letter about whether the agency believes the fix.

What the letter does not do is also on the record. It imposes no restriction on manufacturing, marketing or distribution, requires no recall, and does not block new 510(k) submissions. Olympus will respond within 15 business days, then file periodic updates until FDA judges its actions adequate, and it told investors the letter is not expected to affect financial results. The market took a different view: Tokyo-listed shares fell 13.6 percent on October 14, to 1,756 yen.

The record behind this runs four years and keeps returning to the same addresses. In December 2022 FDA wrote to Olympus Medical Systems about the Hachioji plant, citing four complaints of Uretero-Reno scopes breaking or rupturing during use that the company had not reported inside the 30-day window. In March 2023 it wrote again, about Hinode, citing CAPA failures on a distal cap that was detaching, a 2020 complaint of patient esophageal trauma that went uninvestigated until 2022, 98 complaints never opened under procedure, and six more late reports. Hachioji and Hinode are two of the six sites in the new letter. A third letter, to Aizu Olympus in November 2022, found no written medical device reporting procedures at all, and Aizu is the plant whose output FDA started refusing in June 2025 under Import Alert 89-04, 58 listed device entries covering ureterorenoscopes, bronchoscopes, laparoscopes and automated endoscope reprocessors. In between came a late-2023 Class I recall of more than 17,600 video bronchoscopes after four fires inside patients’ lungs, and a January 2026 recall of three insufflation unit models over software that could over-pressure without alarming, also later classified Class I.

Four years, the same quality system, several of the same plants, and the enforcement ladder has climbed exactly one rung: from letters to a 58-model import alert. That is the part worth sitting with. In that same June 2025 notice, FDA told health care providers they “may continue using these devices if you are not experiencing any problems,” and advised against canceling or delaying procedures without a benefit-risk conversation. In 2025 Olympus held 51.5 percent of the US duodenoscope market and 45.9 percent of gastroscopes. There is no version of a hard stop on Olympus that lands only on Olympus. It lands on GI suites, ICUs and operating rooms. Enforcement against a supplier of that size has a ceiling, and both sides have had four years to work out roughly where it is.

The part worth copying into your own risk register has nothing to do with endoscopes. One inspection campaign produced one letter that reaches a plant in Hamburg and a plant in Minnesota at the same time. FDA is treating a multinational quality system as a single system, which means a finding at a European site is now a US compliance event, and a remediation plan has to satisfy one reviewer across every jurisdiction it touches. Any device company running a shared QMS across borders should assume its exposure is the sum of its sites, not the worst of them.

The timing is the other thing. Olympus is carrying this while cutting roughly 2,000 jobs in a restructuring announced in November 2025, centered on the same endoscopy business the letter covers. Quality remediation is labor. It is documentation, validation, training and the people who do them. Running the largest quality overhaul in the company’s history through a headcount reduction in the same division is a sequencing decision FDA will be grading in writing, every reporting period, until it says otherwise.

Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏛️ BD trades $19B in US factories for tariff relief that is not written yet

BD will invest $19 billion in the US over several years, $3 billion of it in manufacturing expansion across eight sites, to lift domestic supply of essential consumables to roughly 80% and make every US needle domestically from American steel. In return it gets relief from future Section 232 device tariffs, contingent on final scope, implementation, and milestones BD has to hit. The company is not quantifying the benefit, which tells you how firm the other side of this trade is.

BD

2.🧾 AdvaMed wants CMS’s new coverage fast lane widened

Comments on RAPID, the CMS pathway that would hand FDA-designated breakthrough devices a proposed national coverage determination, close October 13. AdvaMed called it a positive step and then asked for most of it to change: broader breakthrough eligibility, diagnostics included, firm NCD timelines, transition protection for devices already queued under older pathways. CMS thinks about 40 devices qualify today, against nearly 1,300 breakthrough designations granted. That ratio is the whole argument.

MedTech Dive

3. 🚨 Four deaths tied to a handheld ultrasound that needs a signal to scan

FDA issued an early alert on Philips Lumify after two software faults: the app can stop recognizing a registered transducer and demand re-registration, which needs Wi-Fi or cellular, and the USB transducer connection can drop mid-scan. Philips has reported eight serious injuries and four deaths, and told customers in a September 24 letter to keep a backup scanner within reach. A point-of-care device whose failure mode is connectivity is a hard thing to sell into an ambulance.

FDA

4. ☢️ GE HealthCare buys the last mile of PET

GE HealthCare will pay $945 million in cash to Trilantic North America for Sofie Biosciences: 15 contract manufacturing sites running 21 cyclotrons, a theranostics CDMO, and US rights to FAPI-74, a Phase 3 PET tracer. Sofie keeps operating independently and keeps supplying rivals’ products. With a 110-minute half-life on F18 tracers, distribution geography is the moat in radiopharma, and GE bought it rather than built it. Close is expected by July 2027.

Radiology Business

5. 💼 Stryker replaces the CEO who tripled it

Kevin Lobo hands the chief executive job to president and COO Spencer Stiles on January 1, 2027, and becomes executive chair. Lobo ran Stryker for 14 years, taking net sales from $8.7 billion in 2012 to more than $26 billion this year across 60-plus acquisitions, Mako included. Stiles joined the Endoscopy business in 1999 and later led the Wright Medical deal and the spine separation. An internal, pre-announced, five-quarter handoff is the opposite of a surprise.

Stryker

6. ⚖️ Apple owes Masimo another $184M, and the clock started in 2020

A California federal court added $184.2 million in prejudgment interest to Masimo’s $634 million pulse oximetry verdict, bringing the total to $818.5 million. The court ran interest from January 2020, when it found Apple should have struck a royalty deal, and used Masimo’s own cost of borrowing, a figure taken from one of Apple’s trial experts. Dating the royalty clock to 2020 instead of the verdict is what turned one nine-figure loss into most of another.

MassDevice

7. 🤖 Robotic microsurgery raises $125M

MMI closed a $125 million Series D led by BioStar Capital, with S3 Ventures, Angelini Ventures, and an undisclosed strategic investor. The Symani system, FDA-authorized and CE marked, pairs wristed microinstruments with tremor reduction and motion scaling; roughly 50 systems are installed and 3,500 procedures done. The money goes to adoption, energy instruments, and the REMIND study. Fifty placements in a decade says microsurgery robotics is a procedure-creation problem, not a selling problem.

MD+DI

8. ✅ A $50M bet that the certification queue is the market

Scarlet, a London certification body designated under EU MDR and recognized by the MHRA and as an FDA third-party reviewer, raised a $50 million Series B led by Headline, with Notion Capital joining Atomico, Creandum, and Kindred. It is one of roughly 52 EU notified bodies and says it is the only one built for software and AI, selling subscription surveillance instead of one-off audits. When a minor update takes six to eight months to clear, the reviewer becomes a vendor choice.

Tech.eu

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Britain just put AI device oversight into law. Washington put it on a guidance list.

On October 6 the UK government accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare. Not 40 of 44, not 44 with caveats. The government response marks every recommendation “Accept” and sorts them into ten priority areas. The third one reads: shift towards stronger post-market assurance.

The commission was the MHRA’s own creation, stood up in September 2025 as an independent, non-statutory body chaired by Professor Alastair Denniston, with England’s Patient Safety Commissioner Henrietta Hughes as deputy. It published its report on September 10 after a year of evidence gathering the government says reached more than 12,000 people. Health innovation minister James Frith wrote that the UK “needs a new approach to AI product regulation in healthcare.” Then the government took the entire list.

Here is what is now on the record. The MHRA will use secondary legislation to update the definition of a medical device and introduce a new classification system for software and AI, following a consultation it intends to launch by spring 2027. Draft guidance on predetermined change control plans arrives in December. Recommendation 17 commits the agency to an enhanced post-market surveillance toolkit, “possibly including legislative reform.” Recommendation 19 commits it to a public database of adverse incident information. Staged authorization pathways get explored, with sandbox provisions riding in the forthcoming Regulating for Growth Bill. A cross-system program board reports quarterly, and an implementation roadmap with named responsibilities lands by spring 2027. AI Airlock, the agency’s regulatory sandbox, is open for applications on three more years of government funding, with the first wave of innovators selected in November and the whole phase pointed at post-market surveillance and lifecycle regulation.

Now set that against what Washington did five days earlier. On October 1, CDRH published its FY2027 guidance agenda. “Marketing Submission and Lifecycle Management Recommendations for Artificial Intelligence-Enabled Device Software Functions” sits second on a seven-item A-list of final guidances, finalizing a draft that has been out since January 2025. “Predetermined Change Control Plans for Medical Devices” is on the same list. The single A-list draft guidance is evidentiary recommendations for generative AI conversational devices for mental disorders. And FDA’s broader generative-AI discussion paper, published August 18, closes comments on October 19 under docket FDA-2026-N-7874 — a paper that asks questions about postmarket monitoring rather than answering them.

Both regulators have reached the same technical conclusion: a device that changes after clearance cannot be governed by a one-time review before it ships. They are filing that conclusion in very different places. The UK is heading toward statute, where the definition of a device and its classification actually change, and a surveillance duty can be written down and enforced. The FDA is heading toward final guidance, which represents the agency’s current thinking and binds no one, as every guidance document says on its own cover page.

The timing is awkward for a specific reason. In April, the MHRA was publicly working with the FDA to align device regulation and identify where future mutual recognition might fit, on top of three reliance routes the UK had already committed to for authorizations from the US, EU, Canada and Australia. Reliance works when both sides want the same evidence file. It is a harder argument when one side’s file carries an ongoing obligation that the other side’s does not. A US clearance can satisfy a UK premarket review. It cannot discharge a UK monitoring duty under UK law.

For anyone with an AI-enabled device and a UK commercial plan, the near calendar is shorter than the spring 2027 headline suggests. The change-management guidance is a December document, which means the drafting is happening now. The classification consultation will decide whether products currently outside device regulation get pulled in, and that is a secondary-legislation question, not a guidance question, which makes it slower to arrive and much harder to argue with once it does. And AI Airlock phase 3 is taking applications with selections in November, which is the cheapest seat available to a company that would rather help write a post-market surveillance regime than inherit one.

Trade coverage has framed the week as the UK backing continuous oversight. The sharper read is that the UK has decided lifecycle oversight is a legal obligation, and the United States has decided, for now, that it is a recommendation. Anyone building a regulatory plan on the assumption that those two converge is betting on a mutual-recognition conversation that just got materially harder.

Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🫀 FDA approves the first heart valve built to grow with the patient

Edwards Lifesciences’ Autus Size-Adjustable Valve won premarket approval for children with congenital pulmonary valve disease. It implants at roughly 13mm and expands by catheter to about 22mm, and it is the first FDA-approved valve using polymeric leaflets rather than animal tissue. Sixty-two patients across 12 US sites, three frame fractures, no deaths or strokes. The win isn’t the valve, it’s the reoperations it removes from a child’s life — and from the lifetime cost case.

FDA

2. 🧠 Terumo buys into the subdural hematoma race before the pivotal reads

Terumo Neuro agreed to buy Arsenal Medical and NeoCast, an investigational solvent-free liquid embolic for middle meningeal artery embolization in chronic subdural hematoma. Terms weren’t disclosed. First-in-human data showed 96% of patients clearing at least half their hematoma volume and 75% resolving completely; FDA granted an IDE for the RADIANT pivotal trial against Medtronic’s Onyx, and patients are already enrolling. Buying the asset before the pivotal reads is what it costs not to be third into MMA embolization.

Terumo Neuro

3. 🏭 A July flood takes $22M off Integra’s year

Flash flooding in July at Integra LifeSciences’ East Side Cincinnati plant damaged equipment and inventory at the site making Mayfield cranial stabilization and Budde halo retractors. Integra now sees roughly $7 million off Q3 and another $15–20 million across 2026, with full recovery pushed to Q2 2027. Guidance fell to $1.634–1.654 billion and the stock dropped about 16%. Single-site concentration is a risk nobody prices until the creek comes up.

MassDevice

4. 🏠 FDA picks its first five for the home-readmissions challenge

CDRH named the first five participants in READI-Home: BD’s capillary self-collection kit, Epitel’s wearable EEG, Current Health’s CAR-T monitoring software, Skribe’s cardiac-function patch, and a Prapela crib mattress that vibrates for infants with single-ventricle heart disease. They get early design and testing feedback plus access to FDA labs. Nine slots total, filled by December 4. Regulatory access as the carrot costs the agency little and arrives years before any payment pathway would.

MedTech Dive

5. 💸 Oura can’t find a price and pulls a $2.2B IPO

Oura postponed its Nasdaq listing on September 29 after marketing 50 million shares at $40–44, about $2.1 billion at a $13.5 billion valuation. CEO Tom Hale said the company has “the luxury of choosing our moment.” Bond and oil volatility took the blame; the book was reportedly five times covered but heavy with insider selling. This was the quarter’s test of whether wearables price as health tech or consumer electronics, and it goes unanswered.

Axios

6. 🇪🇺 Sofinnova raises €82M to build medtechs that don’t exist yet

Sofinnova Partners closed an oversubscribed €82 million MD Start IV to found six to eight device companies across Europe and the US over five years, carrying them from inception through clinical milestones. The prior €63 million fund seeded six companies that raised more than €140 million in follow-on, including LimFlow’s sale to Inari for up to $415 million. Company-creation capital is the thinnest layer of the European device stack, and this is 30% more of it.

Sofinnova Partners

7. 💼 Nyxoah hands its US launch to Teleflex’s former CEO

Liam Kelly, who ran Teleflex from January 2018 until January 2026, took over as Nyxoah’s chief executive on October 1, succeeding Olivier Taelman. Genio, the leadless hypoglossal nerve stimulator for obstructive sleep apnea, has had FDA approval since August 2025 and is early into a US market Inspire built and still owns. Handing an early launch to a large-cap operator says the board thinks the bottleneck is commercial execution, not the implant.

Nyxoah

8. 🧾 Carlsmed’s Medicare codes switch on

Medicare reimbursement for Carlsmed’s aprevo personalized lumbar fusion procedures took effect October 1 under three new MS-DRGs created in the FY2027 inpatient final rule. The company also named Tony Jarc, fifteen years at Intuitive, to a new chief product and AI officer role. A dedicated DRG is what turns a personalized implant from a hospital cost problem into a line item, and that gate, not FDA, is where most AI-shaped hardware stalls.

MassDevice

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The new US-China tariff deal names medical devices. The 77-line list of Chinese goods getting relief doesn’t include one.

The White House published the first real output of the U.S.-China Board of Trade on September 27: two product lists under what the administration calls the “30-for-30” framework, roughly $30 billion of goods on each side recommended for more favorable tariff treatment. U.S. Trade Representative Jamieson Greer’s statement led with the sector by name. “From agricultural products to medical devices,” he said, the administration is “unlocking improved market access for about 30 percent of U.S. exports to China.”

Then you read the lists, and the sentence narrows considerably.

The list of Chinese goods recommended for lower U.S. duties runs 77 lines. Fireworks. Plastic tableware. Bed linen and table linen. Garden umbrellas, artificial flowers, electric shavers, microwave ovens, Christmas-tree lamps, highchairs, child safety seats, toys, billiard tables, fish hooks, artists’ brushes, vacuum flasks. Not one line sits in HTS chapter 90, where surgical, diagnostic and measuring instruments are classified. Nothing in heading 3006 or 3822 either — medical consumables and diagnostic reagents. The closest thing to a medical product on the entire list is 84231000: baby scales.

The medtech relief is all on the other side of the ledger. The companion list of U.S. exports that China will consider for lower duties runs about 1,619 lines, and that is where devices appear. Which means the benefit on offer goes to companies shipping American-built devices into China. It does nothing for the much larger set of companies whose exposure runs the other direction — the ones buying Chinese components, subassemblies, injection-molded parts and finished consumables, which is most of the industry.

And it is worth being precise about what “recommended” buys. The terms of reference value both lists by reference to 2024 bilateral trade figures and state that reductions “will be determined and implemented in accordance with each side’s domestic legal processes.” No rates. No effective date. Deputies may propose adjustments to the lists at least annually. There is no enforcement language and no termination clause. This is a standing bilateral committee with a published agenda, which is more than existed in May, and considerably less than a tariff schedule.

Meanwhile the import side of a device company’s cost structure is exactly where it was last week. Section 301 duties on Chinese-origin syringes and needles stand at 100 percent, in force since September 2024. Gloves went to 100 percent and masks and respirators to 50 percent at the start of this year. None of that is on the 77 lines.

The larger thing still sitting open is the Section 232 investigation into imports of personal protective equipment, medical consumables and medical equipment, including devices. Commerce initiated it September 2, 2025 and published the comment notice on September 26, 2025. Its scope is not narrow: masks, gloves, syringes, IV bags, catheters, sutures, wheelchairs, hospital beds, pacemakers, insulin pumps, coronary stents, heart valves, hearing aids, prosthetics. The statutory report was due at the end of May 2026. Four months past that date, no determination has been announced.

Use pharmaceuticals as the clock. That Section 232 opened April 1, 2025, produced a proclamation April 2, 2026, and took effect July 31, 2026 at 100 percent on patented pharmaceutical imports, with a 15 percent tier for the EU, Japan, Korea and Switzerland and a deferral to September 29 for seventeen named companies. Initiation to proclamation ran about twelve months. The device investigation passed that mark a month ago.

So the trade news this week is better read as a sequencing signal than a cost event. Washington has now built a mechanism that can lower tariffs on Chinese consumer goods at an annual cadence, named medtech in the press release for the export-access half of it, and left the half that would actually reduce the landed cost of a device untouched — while keeping a national-security tariff instrument loaded and pointed at the same category. AdvaMed, MDMA and the American Hospital Association all filed against device tariffs last fall. None of them got a decision; they got a trade board.

For anyone modeling 2027 COGS, the practical read is that the downside case on Chinese inputs has not been retired and the upside case on Chinese market access is a recommendation with no number attached. Companies with U.S. manufacturing and a China sales motion have a reason to look at the 1,619-line list for their own codes this week. Everyone else should assume their input costs are a policy decision someone else has not made yet, and should not build a plan that needs that decision to go their way.

Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🤖 FDA writes down what it wants from surgical robots

CDRH issued draft guidance on premarket submissions for robotically-assisted surgical devices, covering non-clinical testing, clinical data and labeling expectations. Comments close November 24 under docket FDA-2026-N-9505. The agency also scheduled a public workshop on benefit-risk for robotic devices with autonomous or remote teleoperation features. The timing matters: a half-dozen platforms are mid-clearance and have been guessing at the evidence bar. A written bar is easier to clear than an inferred one, and harder to argue with.

FDA

2. 🧬 Advisers back the first multi-cancer blood test, barely

The Molecular and Clinical Genetics Panel voted 7-2-1 that Galleri’s benefits outweigh its risks, was unanimous on safety, and split 6-4 on effectiveness. GRAIL’s PMA rests on PATHFINDER 2 and NHS-Galleri, which together found four to seven times more cancers than standard screening alone. FDA decides in the coming months and is not bound by the vote. That 6-4 effectiveness margin is the number every MCED developer behind Grail should be reading.

The ASCO Post

3. ❤️ Impella controller recall goes Class I after three deaths

FDA classified Abiomed’s removal of Automated Impella Controllers as Class I, citing purge-cassette recognition failures that trigger alarms and delay circulatory support. Thirty-seven serious injuries and three deaths were reported as of August 17; Abiomed notified customers August 12. Hospitals keep using existing units and fall back to spares while service replaces the part. A component-level defect on a market-leading platform, managed as a service call rather than a pull.

FDA

4. 💼 Jana tells Cooper’s board to sell divisions and replace the CEO

Jana Partners sent a letter pressing Cooper Companies to divest businesses, replace CEO Albert White and install a new chair, after the board unanimously voted to keep CooperSurgical. Cooper cut 2026 revenue guidance to $4.23–$4.25 billion; CooperVision’s quarter was flat at $717.0 million. Browning West has pushed a pure-play vision case since November 2025. A failed process plus lowered guidance is the combination that turns one activist letter into two.

MassDevice

5. 📉 Adagio cuts 25 of 43 employees and opens a strategic review

Adagio Medical laid off 25 of its 43 full-time staff, booked $1.3 million in severance, and began exploring a sale, merger or acquisition. It held roughly $7.7 million in cash mid-year and faces Nasdaq delisting over the $2.5 million equity minimum. Shares closed at 23 cents against a $2.58 52-week high. The vCLAS ventricular cryoablation system is still sitting at FDA on a PMA — the asset outlived the company’s ability to fund it.

Fierce Biotech

6. 🌏 Fresenius walks out of the cheap end of China

Fresenius Medical Care will stop making and selling the 4008A hemodialysis system in China and exit the country’s peritoneal dialysis business, taking about €110 million in impairment, scrappage and termination costs in Q3. China is 6–7% of Care Enablement revenue. The company is betting on the 5008S and multiFiltratePRO instead. The 4008A launched in 2019 as an emerging-market value play; value turned out to be the one position that does not pay.

Fresenius Medical Care

7. 🩸 First sirolimus drug-eluting balloon clears FDA

FDA approved Cordis’s Selution SLR for coronary in-stent restenosis on September 21, the first sirolimus-coated balloon in the US and only the second drug-coated balloon overall after Boston Scientific’s Agent in 2024. SELUTION4ISR showed noninferiority to standard care on one-year target lesion failure. Cordis also finished enrolling 960 patients in SELUTION4DeNovo for small-vessel de novo lesions — the indication where the balloon-versus-stent argument actually gets settled.

TCTMD

8. 🧪 Siemens Healthineers and Novo go looking for liver disease together

The two are partnering on US awareness and triage for MASLD and MASH, built around Siemens’s ELF blood test for advanced fibrosis risk — no biopsy, no specialized imaging. Roughly a quarter of US adults have MASLD and most do not know it. Novo has Wegovy approved in noncirrhotic MASH; Madrigal’s Rezdiffra opened the category in 2024. Pharma paying to find the patients is the closest thing diagnostics gets to a free sales force.

Fierce Biotech

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Medicare's lab pay reset finally lands, and molecular diagnostics absorb the deepest cuts.

CMS posted preliminary Clinical Laboratory Fee Schedule rates for 2027 on Monday. Of roughly 1,500 codes with usable private-payer data, 1,171 came back with a weighted median below what Medicare pays today. Another 186 went up, 169 held flat, and 419 returned no usable data at all — those go to an expert panel CMS convened on September 15 and 16. The agency’s own summary puts the average potential change at about 16 percent below current rates.

CMS framed it as a correction rather than a cut. Administrator Mehmet Oz said Medicare has been paying roughly 16 percent more than commercial insurers for identical tests, and the agency estimated the adjustment saves taxpayers about $1 billion a year. Statute caps any single test at a 15 percent reduction per year, so the full repricing phases across 2027, 2028 and 2029. The American Clinical Laboratory Association counts 775 tests that hit that ceiling in year one. Quest Diagnostics closed down nearly 5 percent on the news; Labcorp fell more than 3 percent.

The damage is not evenly distributed, and that is the part device leaders should read closely. Routine chemistry lands near the 16 percent average. Molecular pathology and genomic sequencing panels face steeper reductions. Proprietary laboratory analyses — the PLA codes a company obtains for a single branded assay — move barely 2 percent. The spread rewards exactly what it looks like it rewards: a test with its own code, its own evidence file and no direct comparator holds its price. A test that sits in a crowded code with a dozen competitors reporting rates does not.

What makes this cycle different is that it is happening at all. PAMA passed in 2014 and produced three years of cuts up to 10 percent, then six years of freezes as Congress delayed the mechanism almost annually. The most recent delay rode in on the bill that ended the government shutdown, signed February 3, 2026, which blocked the 2026 cuts and pushed the data reporting window to May 1. Labs reported through the end of July; 6,411 NPIs submitted, 6,304 survived quality screening. The bipartisan RESULTS Act would cap annual reductions at 5 percent, exclude Medicaid managed care rates from the reporting pool, and move rate-setting to a four-year cycle. It carries 121 House cosponsors and has not moved out of committee.

So the industry’s argument now has to be made against the data rather than against the schedule, and the industry does not like the data. ACLA calls the sample “a distorted and incomplete picture of the market,” noting the rates rest on reporting from roughly 2 percent of labs Medicare Part B paid in 2024.

There is a wrinkle in that complaint worth flagging, because it cuts the other way. Hospital outreach labs, which commercial plans reimburse at multiples of independent lab rates, made up 13.6 percent of the reporting pool this cycle — 875 of 6,411 labs — against 1.1 percent in 2017. Their participation pulled the weighted medians up. The cuts landing in November are already the moderated version. Had the reporting pool looked like it did in the first cycle, the numbers would be worse.

For anyone whose commercial model runs through a CLFS code, the practical read is narrow and immediate. The comment window is 30 days from September 21. CMS finalizes in November. Rates take effect January 1. That is not enough time to change the arithmetic, and comment letters have not historically moved preliminary CLFS rates much. What it is enough time for is to find out which of your codes are in the 775, model the three-year glide rather than the first-year hit, and decide whether the assay you are building a business around survives the rate it will be paid in 2029.

The larger signal is about where diagnostics value gets defended. Reimbursement built on a market-rate benchmark punishes commodity positioning by design, and the benchmark is now running on schedule after nine years of not running. Differentiation that exists only in a sales deck will price like a commodity, because the code it bills under is a commodity. Differentiation that exists in a distinct code, backed by evidence a payer can read, is the only thing in this rate file that held its value.

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🦾 A Paradromics implant let a woman with motor neuron disease answer questions out loud

Paradromics says its first Connect-One participant — a woman in her 60s who lost her speech to progressive motor neuron disease — used the company’s 400-electrode implant to choose her own words and answer open-ended questions. She was implanted in June. The feasibility study will enroll up to 10 people across the University of Michigan, Mass General and UC Davis. Cursor control was a demo. Conversation is a product, and it forces the reimbursement question nobody has answered: what is restored speech worth, and to whom.

MassDevice

2. 🫀 FDA created a device category for AI heart-attack triage

FDA granted De Novo authorization to Powerful Medical’s Queen of Hearts, an AI ECG model that flags acute coronary syndrome — including STEMI and its equivalents — for urgent cardiologist review. The company says the model has caught more than 120,000 heart attacks in Europe since CE marking, at roughly twice the sensitivity of standard care. De Novo creates the classification, not just the authorization. Every AI ECG triage tool behind this one now has a predicate to point at.

MPO

3. 🇬🇧 The UK wants to regulate AI features, not AI products

The MHRA’s National Commission into the Regulation of AI in Healthcare published 44 recommendations urging a lifecycle approach to AI-enabled devices — assess only the functions that meet the device definition rather than whole software systems, allow staged authorizations that widen as evidence accrues, and add financial penalties for non-compliance. If Britain scopes regulation to functions instead of products, US developers get a cheaper second front door — and one more divergence to manage.

GOV.UK

4. 🫁 Mindray is taking the ventilator business Philips walked away from

Mindray launched its SV70 non-invasive hospital ventilator in the US, built to run on Philips V60 accessories and sharing the touchscreen of its own SV900 and SV700. Philips discontinued the V60 line after recalls and will service it through December 2029; Medtronic left ventilators in 2024. Recall exits leave installed-base vacuums, and Mindray is filling this one with accessory compatibility — the cheapest switching cost a hospital can be offered.

MassDevice

5. 🧬 Mayo Clinic and Thermo Fisher are building a million-biospecimen dataset — and Mayo owns most of it

Mayo Clinic and Thermo Fisher launched Precure, LLC, majority-owned by Mayo, to link genomic, proteomic and longitudinal clinical data from one million biospecimens and find disease signals before symptoms appear. Terms weren’t disclosed. The structure is the story: a health system taking majority ownership of the data asset rather than licensing access to it. Anyone negotiating a health-system data partnership this quarter now has a harder comparable to argue against.

Mayo Clinic News Network

6. 🧠 Telix wins US approval for a brain-tumor PET agent the FDA rejected last year

FDA approved Telix’s Pixclara to distinguish recurrent or progressive glioma from treatment-related change in patients one month and older — the first FET-PET imaging drug cleared in the US, after an April 2025 rejection asking for more confirmatory evidence. Gliomas make up roughly 80% of malignant brain tumors, about 24,000 US cases a year. International guidelines already recommended FET-PET; the gap was regulatory, not clinical. A complete response letter is not a death sentence.

Fierce Biotech

7. 🔬 A robotic colonoscope cleared the FDA on a 50-patient study

Neptune Medical won 510(k) clearance for Triton 1, a robotic endoscopy system for diagnostic and therapeutic colon procedures. Its 50-patient CARE 1 study reported a 54.2% adenoma detection rate against a 35% benchmark, with no adverse events. Neptune raised $97 million in Series D in 2024, partly from Olympus. Surgical robotics fights over procedure counts in the hundreds of thousands. Screening colonoscopy is a volume business an order of magnitude larger.

MedTech Dive

8. 💉 Beta Bionics cleared a patch pump and pulled its launch forward

Beta Bionics announced FDA clearance of Mint, a reusable patch pump with a 200-unit reservoir and three-day wear plus a 12-hour grace period, alongside a next-generation dosing algorithm, 3D Intelligence, filed separately. Full US launch moves up to Q1 2027, with at least 1.5 million disposables planned for the year. Insulet’s Omnipod 5 has had the tubeless category largely to itself. It now has a same-form-factor challenger with a pharmacy-channel plan.

Beta Bionics investor relations

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

J&J paid $400 million for an early-stage heart device. Three years later, the team that built it owns it again.

A new company called Jaguar LAA, based in Santa Rosa, California, says it has acquired the Laminar left atrial appendage program from Johnson & Johnson. Terms weren’t disclosed. Santé Ventures and members of Laminar’s former management put together Jaguar, and its CEO is Randy Lashinski, who ran Laminar before the sale and worked at J&J after. Part of the development team goes with him.

J&J bought Laminar in November 2023 for $400 million upfront, with clinical and regulatory milestones on top, and took an in-process R&D charge worth roughly 17 cents of adjusted EPS that year. The evidence behind that price was an early feasibility study of up to 45 patients. At the time of the deal, BTIG’s analysts had 12-month results on 15 of them: every closure successful, no safety events, no device-related thrombus.

The pitch was mechanical. Boston Scientific’s Watchman and Abbott’s Amulet expand inside the appendage and seal it, which leaves an implant facing the bloodstream. Laminar’s catheter gathers the appendage tissue from the inside, rotates it shut and holds it there, so the pouch is eliminated and very little hardware stays exposed in the left atrium. If that works, the argument for less device-related clotting and a lighter drug regimen writes itself.

Biosense Webster started the pivotal IDE study in February 2024: 1,500 patients, up to 100 U.S. sites, randomized against the commercial devices. Enrollment was suspended in mid-2025. The ClinicalTrials.gov record gives the reason as potential unwrapping of the appendage after implant, with “clinically significant leaks.” A twist that doesn’t stay twisted is exactly the kind of failure 15 patients at one year won’t show you and a few hundred will.

J&J told MedTech Dive the sale reflects a “disciplined approach to portfolio management” and gives the program dedicated ownership. That’s a reasonable description. J&J is spinning out orthopedics, and the same Biosense Webster unit that housed Laminar has a pulsed field ablation fight on its hands.

The other half of the story is what happened to the market while the trial was paused. Watchman sales grew nearly 30% in 2025, to $1.96 billion. By the second quarter of this year that growth was 4.3%, and Boston Scientific cut guidance in part because standalone Watchman procedures are declining. Mike Mahoney told investors he expects the second half to shrink and isn’t assuming any Watchman growth in 2027.

Put those together and J&J’s decision gets simple. In 2023 it paid a growth-market price for feasibility-stage evidence. By 2026 the device needed a fix and, presumably, a new trial, and the category it was supposed to enter had stopped growing. Funding a redesign and another four-figure randomized study inside a company with better uses for the money is a hard case to make.

For anyone building toward an exit, the sequence matters more than the outcome. Laminar’s investors were paid on 15 patients. The acquirer then ran the experiment that mattered, a randomized comparison against two entrenched devices, and absorbed the result. That is the trade a strategic makes when it buys early, and it is why upfront-versus-milestone structure deserves as much attention as the headline number. The $400 million cleared. The milestones were tied to clinical and regulatory progress that didn’t arrive.

Jaguar starts with things most startups don’t have: a device that has been through a large trial, the people who built it, and a detailed picture of how it fails. What it hasn’t said is whether the unwrapping problem is a design issue, a patient-selection issue, or something harder. Santé didn’t answer MedTech Dive’s question about whether a new trial is planned. Until that’s clear, the differentiated mechanism is still a hypothesis, only now it’s being tested on venture money instead of J&J’s.

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏛️ CMS finalizes TAVR coverage for asymptomatic severe aortic stenosis

On Thursday CMS finalized the TAVR national coverage determination it has been reconsidering since Edwards’ request last year. Medicare now covers asymptomatic severe AS under a coverage-with-evidence-development requirement, and symptomatic severe AS loses its CED requirement entirely. Heart-team and on-site cardiac surgery requirements stay. This is the reimbursement half of a two-part expansion; the FDA label came earlier this year. Edwards and Medtronic get a larger addressable patient pool at the exact moment structural-heart growth was decelerating, and every hospital TAVR program now has a reason to revisit its referral funnel.

Cardiovascular Business

2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

3. 🛡️ Stryker’s cyberattack fallout stretches into Q4, stock hits 52-week low

CFO Preston Wells told the Wells Fargo conference that peripheral vascular supply disruptions from the March attack, which management said in July would be manageable by end of Q3, will now run into Q4, and that the constraint is blocking new business wins, not just fulfillment. Hip sales were soft too. Shares fell roughly 10% on the week and Wells Fargo cut its target by $70 while keeping the rating. Guidance held. Meanwhile Boston Scientific said it has fully restored manufacturing and shipping after its own August incident. The lesson from both: the market is now pricing cyber resilience as an operating metric, and “we’re back online” and “we’re back to full inventory” are separated by quarters, not days.

MedTech Dive

4. 🤖 Intuitive publishes a 14-million-case meta-analysis backing da Vinci in benign surgery

A systematic review in Annals of Surgery Open, led by a Mass General Brigham surgeon with Intuitive co-authors, pooled 366 studies across 32 countries and found robotic surgery associated with better select perioperative outcomes than laparoscopic and open approaches across 13 benign conditions. The timing is the story. Medtronic’s Hugo and J&J’s Ottava both cleared for U.S. soft tissue within the past year, and benign general surgery is precisely where bears expect share loss. Intuitive is choosing to compete on the evidence base rather than the hardware, which is the one asset a new entrant can’t buy.

Intuitive Surgical

5. 🦴 Zimmer Biomet splits its Americas leadership ahead of the Monogram robot

Zimmer promoted three executives into a new three-way structure (Americas commercial, global recon portfolio, and a standalone robotics/technology/data president) and parted with former Nevro CEO Kevin Thornal, who leaves Sept. 30 after roughly a year. The stated purpose is to build a dedicated robotics sales force before the 2027 Monogram launch, in parallel with the ongoing conversion of its 2,500-person U.S. sales force from contractors to employees. The same week, Zimmer proposed cutting 580 jobs at its Winterthur, Switzerland plant. Reorganizing the commercial org before the product exists is the right sequence; it’s also a lot of change to absorb at once.

MedTech Dive

6. ⌚ Apple Watch Ultra 4 ships a readiness score, not a blood pressure reading

Apple unveiled the Ultra 4 with a redesigned sensor system on its S11 chip: more frequent HRV sampling, a daily readiness score, a “Health Age” metric, and what Apple calls the most accurate heart-rate sensing in a wearable, per its own 1,000-participant study. The blood pressure feature that dominated pre-event reporting didn’t make it. Read alongside Oura’s S-1 last week, the picture is clear: the consumer wearable majors are converging on the same recovery-and-readiness lane and holding their regulated features in reserve until the FDA process finishes.

MassDevice

7. 🧠 Nvidia takes an equity stake in Verily

Verily extended its March $300M round with new money from Nvidia and a follow-on from CU Healthcare Innovation Fund; terms weren’t disclosed. The two companies already collaborate on Verily’s Pre data platform and the Forecast 1.0 foundation model that fuses genomics with EHR data. Nvidia converting a technology partnership into a shareholding is a pattern it’s repeating across healthcare AI, and it’s worth watching for anyone whose device roadmap assumes a neutral compute layer underneath.

R&D World

8. 🔬 Galleri goes to an FDA advisory panel Sept. 23; public docket closes Wednesday

A look-ahead: the Molecular and Clinical Genetics Panel meets a week from Wednesday to vote on GRAIL’s PMA for the Galleri multi-cancer early detection test, the first MCED to reach an FDA panel. The public comment docket (FDA-2026-N-8004) closes Sept. 16. The PMA rests on PATHFINDER 2 and the NHS-Galleri trial. The panel’s vote is non-binding, but the questions it asks about how a screening test with modest sensitivity fits into a population program will set the frame for every MCED that follows.

FDA

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Oura Is Going Public on the Wellness Exemption

Oura filed to go public on September 3, with a planned Nasdaq listing under OURA and Goldman Sachs, Morgan Stanley and J.P. Morgan on the cover. The numbers are the kind most device companies never see: $1.21 billion in revenue for the nine months to June 30, up 74%; $974 million of it hardware, $240 million recurring membership; a 55% gross margin; $60.8 million in net income. Paid members doubled in a year to 5.0 million. The Wall Street Journal has reported a valuation north of $11 billion.

Buried in the risk factors is the sentence that matters for this audience. Oura markets its products as general wellness tools it believes are not subject to FDA device requirements. Then it tells investors it expects features it introduces going forward to be regulated as medical devices.

That is not a hedge. It is the plan, and the company has been executing it in the open.

In January the FDA loosened its wellness guidance, giving wearables room to surface trends in measures like blood pressure without crossing into device territory. Oura moved in May: it shipped a nighttime blood pressure trend feature under the wellness exemption, one that deliberately shows no systolic or diastolic numbers, while running a separate IRB-approved study of an algorithm meant to flag hidden hypertension. That second feature is intended to go through FDA. As of June 30, the study had enrolled more than 350,000 participants.

Read that number the way a clinical-stage device company would. Oura recruited a hypertension study population larger than most registries by pushing a notification to people who had already paid $349 to $499 for the sensor and $5.99 a month for the app. Members wear the ring a median of 23 hours a day. Twelve-month paid retention is roughly 85%. The company holds nearly 42 billion hours of longitudinal biometric data. Evidence generation, for Oura, is a feature rollout.

This is the device commercialization sequence run backward. The standard playbook is intended use, then evidence, then clearance, then reimbursement, then a sales force, then scale. Oura built the installed base and the habit first, then the data, and now proposes to buy regulation one feature at a time, only where a cleared claim is worth more than a wellness one. Its partnerships with Dexcom, ResMed and Eli Lilly, which holds a SAFE note converting at the IPO, let it borrow clinical pathways without owning them. ResMed’s deal routes ring users with breathing disturbances toward a clinician, so Oura never has to claim it detects sleep apnea.

The wellness line cuts both ways, though, and the S-1 knows it. A proposed class action in the Northern District of California argues Oura’s sleep-stage accuracy is no better than a coin flip; the prospectus lists accuracy litigation as a standing risk. More than half of members report a chronic condition, and 80% of those say they use Oura data to inform decisions about it. The company presents that as a strength. A regulator reading intended use might not. And once Oura holds a cleared hypertension feature, every accuracy claim on the adjacent wellness features will be read against a clinical standard, whether or not the FDA asks.

There is also the capital structure. The filing shows a $985 million deemed dividend to preferred holders and a $742 million net financing outflow for the period, meaning early investors took substantial liquidity before public buyers arrive. Net income is real; the $924 million net loss attributable to common stockholders is an accounting artifact of that transaction.

For device operators, the uncomfortable takeaway is this. The largest new public company in health hardware this year has never submitted a 510(k), and it is walking into regulation from a position of five million paying users rather than toward it from a position of zero. Clearance-first sequencing is still the safe path for anything that goes inside the body. For anything that sits on it, Oura just filed the case that it may no longer be the fast one.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The theme this week is follow-through. Almost every story is the second chapter of something you already read: a cyberattack that was “contained” and is now a guidance cut, a $13.1 billion acquisition whose brand is being retired, a plant bought out of a competitor’s collapse that’s now closing, a spinout that has stopped being a spinout and started being a company. The announcement is never the story. What the company does eleven days, or two years, later is.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🔐 Boston Scientific says the cyberattack will hit Q3 and full-year results

A September 7 SEC filing says last month’s attack is “likely to have a material impact” on Q3 and full-year 2026, and that both guidance ranges are now “unlikely.” Manufacturing and shipping are largely restored, but the backlog will take time and only “some portion” of lost revenue will be recovered. Stryker held full-year guidance through its March attack; Boston Scientific is the first large-cap this year to concede the year to a breach — in a week that also brought a recall of Infinion CX spinal cord stimulator leads tied to 1,081 serious injuries.

Fierce Biotech

2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

3. 🦾 Stryker signs a definitive agreement to acquire ZuriMED

Stryker is buying privately held ZuriMED and its commercialized FiberLocker System, which anchors a rotator cuff patch across the full patch-tendon interface rather than at suture points. Terms weren’t disclosed. This is a failure-mode acquisition, not a category acquisition: the target is the re-tear, and the product rides surgeon relationships Stryker already has. That’s the tuck-in profile every strategic says it wants.

Stryker

4. 💉 MiniMed files its first patch pump with the FDA and raises guidance

The Medtronic spinout posted Q1 revenue of $843 million, up 17%, raised full-year organic growth to 10.5%, and disclosed an FDA submission for MiniMed Fit — a tubeless pump with a 300-unit reservoir and up to seven days of wear, targeted for next summer — alongside completed pivotal enrollment for a fully closed-loop algorithm and CE mark for Flex. Read the Fit specs against Insulet: reservoir size and wear time are aimed at Type 2 patients on higher insulin volumes, where Omnipod’s lead is most exposed.

MedTech Dive

5. 🏷️ J&J MedTech is retiring the Shockwave Medical name

Effective October 1, Shockwave Medical becomes Johnson & Johnson MedTech and its IVL portfolio becomes “circulatory restoration solutions”; the name survives only on the products. J&J paid $13.1 billion in May 2024. Twenty-eight months is the shelf life of a category-defining brand inside the world’s second-largest device company. If you’re negotiating a sale and telling yourself the acquirer will “keep the brand,” this is what that looks like.

MassDevice

6. 🩻 GE HealthCare secures CE mark for Photonova Spectra photon-counting CT

The CE mark follows FDA clearance and Japanese approval in March, opening Europe for GE’s Deep Silicon detector platform. Silicon is the wager: a different detector material to differentiate in a segment Siemens has owned since the first photon-counting clearance in 2021. Three major markets in six months is the cadence of a company making up for arriving late.

Medical Device Network

7. ⚡ Abbott wins FDA approval for its dual-energy TactiFlex Duo ablation catheter

Duo delivers pulsed field and radiofrequency energy from one catheter, switchable mid-procedure; U.S. cases begin in the coming weeks. CEO Robert Ford has said Duo and Volt are the two products Abbott is counting on to regain EP share in the back half. J&J’s dual-energy catheter was approved in July, so the market has moved past “PFA or not” to “how many energies per catheter.” Single-modality PFA entrants now have a spec-sheet problem.

MedTech Dive

8. 🏭 Zoll is closing the California ventilator plant it bought from Vyaire

Zoll, part of Asahi Kasei, is shutting the Palm Springs plant it acquired in 2024 with select Vyaire ventilator assets; a WARN notice lists 78 employees affected. Two years is roughly how long the integration math on a distressed-asset deal takes to resolve, and it usually resolves toward the acquirer’s existing footprint. In a carve-out, the site is rarely part of what’s being bought.

MassDevice

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Medtronic Just Paid $700 Million to Sell Someone Else's Robot

Medtronic will distribute a rival soft-tissue robot alongside Hugo in China, Singapore and Europe. Enovis, the same day, bought its robot outright.

Medtronic spent the better part of a decade and an undisclosed fortune building Hugo. On Tuesday, it announced it would put roughly $700 million into Cornerstone Robotics, a Hong Kong company whose Sentire system competes for the same soft-tissue procedures, and distribute that robot alongside Hugo in China, Singapore and Europe.

The structure matters. This is an investment plus distribution rights, not an acquisition. Cornerstone keeps ownership of the platform and its IP. Medtronic gets a second console to put in front of hospitals that, for whatever reason, don’t want its first one.

Sentire is not a science project. It won CE mark in May for general, gynecologic, thoracic and urologic surgery, was approved in China in 2024, and is cleared in Singapore. Cornerstone raised about $200 million last November and operates a 30,000-square-meter manufacturing facility in China. The system has dual-console capability and an immersive console architecture that Medtronic’s own release describes as “a familiar configuration” — industry shorthand for something that looks and feels like da Vinci.

Hugo, by contrast, is less than a year past its first U.S. clearance, in urology, with 510(k)s pending for general surgery and gynecology. It is installed in more than 35 countries, and Medtronic expects total procedures to pass 50,000 by fiscal year-end on roughly 250 installed units.

On the earnings call the same morning, an analyst asked CEO Geoff Martha whether the deal signaled doubt about Hugo. “It’s just the opposite,” Martha said, calling it “a global play” and “one of a number of investments we’re making in soft tissue.” Global robotic penetration, he noted, is still in the single digits, and in emerging markets closer to 1%.

Read those two facts together and the strategy is legible. Medtronic is not hedging Hugo. It is conceding that one platform, priced and configured one way, cannot capture a market this early and this fragmented. Hospitals in Shenzhen and hospitals in Stuttgart are not buying the same robot for the same reasons at the same price. The company’s release says it plainly: “flexibility across clinical settings, procedural needs, and economic models.” That last phrase is the one to underline. Economic models. The technology was never the binding constraint on robotic adoption. The capital cost, the service contract, the per-procedure consumables, the utilization math a CFO has to defend — those were.

The same day, Enovis chose the opposite instrument. The orthopedics company agreed to buy France-based eCential Robotics for €155 million upfront and up to €35 million in milestones. eCential built J&J’s Velys Spine robot. Enovis had already been collaborating with it; now it wants the roughly 50-person team in-house to ship a knee robot in late 2028 and a shoulder robot in 2029. CEO Damien McDonald told investors the rationale was “agility.” The market’s response was a 16.5% share-price drop, mostly on margin dilution.

Two companies, one day, two answers to the same question: when you’re behind in robotics, do you build, buy, or distribute? Enovis, with no robot and a competitive gap its own analysts call its most notable, bought the capability. Medtronic, with a robot and a global ecosystem already in place, bought the option to sell a second one without absorbing the platform risk.

Neither is obviously right. Enovis now owns the engineering but also owns 2027’s margin hit and two launch dates it has to hit. Medtronic keeps its balance sheet lighter but has to manage a sales force selling two competing consoles and explain to every Hugo customer why the other robot exists.

What both deals share is an admission that the era of the single flagship robot is ending before most of the flagships have fully launched. Intuitive built one platform and let the market come to it. Its challengers, arriving into a market where the incumbent already sets the terms, are discovering they may need several.

Medtronic also disclosed a smaller move Tuesday: up to $80 million into Pi-Cardia, a structural heart company, with an option to acquire. Same architecture. Stake first, ownership later, if the numbers hold.

For anyone building a device company: the largest strategics are increasingly structuring their commitments as options, not acquisitions. That changes what “a partnership with Medtronic” means when it shows up in a term sheet.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Last week was a lesson in dependencies. A single intrusion stopped one of the world's largest device makers from shipping product. A single component inside a heart-pump controller is now tied to three deaths. A single patent judgment attached a 6% royalty to eleven of a liquid-biopsy company’s products for the next seven years. An activist told a heart-failure implant maker that going it alone is the risk. And the administration is reportedly adding two deputy commissioners at the FDA — one of them for AI — to tighten its grip on the agency. The companies that had the better week were the ones that removed a dependency: Abbott got the first sensor that watches ketones so patients don’t have to, and Roche got a blood test that can stand in for a PET scan. Know what you’re leaning on. Know who controls it.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🔒 Boston Scientific’s ordering and shipping disrupted in cyberattack

Boston Scientific disclosed a cyberattack that has affected its ability to process and ship customer orders, describing a global disruption to operations in an SEC filing; the company identified the attack on Tuesday and has not said how long the disruption will last. Employees at its Cork, Ireland manufacturing facilities were sent home because they couldn’t work, and by Saturday the company said the unauthorized activity appeared limited to certain on-premise systems, with no impact to cloud-based systems, and that it is working with CrowdStrike. Stifel analysts flagged increased uncertainty around the company’s 2026 revenue, margin and EPS outlook. This is the fourth major medtech intrusion of 2026 after Stryker, Intuitive and Medtronic — and the first where the headline damage is a stopped shipping dock rather than stolen data. If your hospital customers are asking about your business-continuity plan this week, that’s why.

MedTech Dive

2. 🧭 Most device companies don’t fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

3. ❤️‍🩹 FDA flags recall of all Impella heart-pump controllers after three deaths

The FDA issued an early alert after Abiomed told customers to remove all Automated Impella Controllers from where they’re used or sold due to purge cassette recognition failures; as of August 17 the company had reported 37 serious injuries and three deaths. J&J says the issue appears in 0.2% of cases, that hospital inventory can keep being used to maintain continuity of care while replacements are scheduled, and that it will swap the purge flag and purge retainer components during annual preventive maintenance or through field-service outreach. Controller issues were tied to recalls in July, September, October (twice) and December 2025 and again in May, which means the company’s most important acquisition since 2022 has now spent more than a year in near-continuous field action. Watch how the language shifts from “correction” to “remove all.”

Cardiovascular Business

4. 🩸 Abbott wins FDA nod for the world’s first dual glucose-ketone sensor

Abbott received De Novo authorization for Libre Duo 10 Day, a dual-analyte sensor that continuously measures glucose and ketones, wearable for 10 days by people with diabetes ages two and up who take insulin or other glucose-lowering medications; it received CE mark in May. The company says it’s the first system to meet both the FDA’s iCGM standard and a new integrated continuous ketone monitoring standard, which establishes a benchmark for continuous ketone monitoring in the U.S. — in other words, Abbott didn’t just win a clearance, it helped write the special controls every follower will now have to meet. Integration with Beta Bionics’ iLet and Sequel’s twiist is expected by year-end, with Insulet and Tandem in 2027; William Blair expects the sensor to be most competitive in pediatrics once it’s pump-integrated, since Dexcom’s approved pediatric sensors are also 10-day. Abbott receives FDA nod for dual-analyte sensor | MedTech Dive +3

MD+DI

5. 🧠 FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment

Roche’s Elecsys pTau217 plasma test is cleared for people 55 and older with signs of cognitive decline, used alongside clinical information to assess Alzheimer’s risk. Developed with Eli Lilly, it’s the first FDA-cleared single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology using the same cutoffs across primary and specialty care, and it runs on existing lab instrumentation without new hardware. Labcorp and Quest both plan to offer it. The strategic read: a test that can rule out in primary care changes who gets referred for PET and CSF workups — and who doesn’t — which matters to anyone selling into the anti-amyloid infusion channel.

MassDevice

6. ⚖️ Guardant ordered to pay $245M in DNA-sequencing patent dispute

A U.S. district court entered final judgment ordering Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University of Washington, upholding a November 2023 jury verdict that Guardant willfully infringed two Duplex Sequencing patents; Guardant must also pay a 6% ongoing royalty on 11 products and services through patent expiry in March 2033. The covered products include Guardant360, Guardant Reveal and Guardant Shield, though Guardant says it will appeal, that updated versions of Reveal and Shield are excluded from the royalty order, and that it continues to challenge the patents at the USPTO. Execution of the judgment and royalty collection are stayed pending appeal. Six points of gross on your flagship products for seven years is a licensing negotiation you’d rather have had in 2019.

Medical Device Network

7. 📣 CVRx has an activist investor urging it to get acquired

Pointillist Family Office founder Jorey Chernett, who holds 5.5% of CVRx, publicly told the Barostim maker’s board it should sell to a large device company with an established heart-failure and EP sales force, national payer relationships to resolve the prior-authorization impasse, and a balance sheet to fund the pivotal work already underway — citing a second-quarter report in which the company cut revenue guidance and disclosed a DOJ civil investigation into sales and marketing practices. Shares had lost a third of their value in a month before the letter; the board says it’s open to constructive engagement, and Johnson & Johnson already owns 15.2%. The argument isn’t that the device doesn’t work — it’s that reimbursement, sales coverage and trial funding are a scale problem a $3 stock can’t solve alone. Expect that thesis to get applied to other single-product neuromod names.

MassDevice

8. 🏛️ HHS plans new FDA deputy commissioner roles for technology and drugs

HHS is planning to appoint two new deputy commissioners at the FDA — one for technology, including health and AI, and one for drugs — in what some in the administration view as a bid to exert greater influence over the agency; no final decisions or announcements have been made. Jared Seehafer, an FDA senior advisor and device-industry veteran who co-founded the compliance software company Enzyme, is the leading candidate for the technology role, which would oversee both the agency’s internal use of AI and its review of AI-enabled products. Both roles would report to commissioner nominee Heidi Overton, who still needs Senate confirmation. Put this next to the generative-AI discussion paper from two weeks ago: the docket closes October 19, and the person who may end up owning the answer is a device-software founder.

CNBC

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The Order Desk Goes Dark, Again

Boston Scientific found something wrong in its network on Tuesday morning. By Wednesday it was telling the SEC that it could not reliably take or ship customer orders anywhere in the world, and that it did not know when it would be able to again.

The company’s statement is short. A cybersecurity incident affecting certain IT systems caused a network outage and disrupted operations, including “the ability to process and ship customer orders.” Incident response protocols are active, third-party forensics firms are in, and systems are coming back in phases. The 8-K adds the sentence investors were looking for and didn’t want: the timeline for full restoration is not yet known, and the company hasn’t determined whether the impact will be material. A spokesperson told Cybersecurity Dive the same thing. Shares fell nearly 6% before the open.

Nobody has said ransomware. Nobody has named a threat actor or an entry point. What the filing does say is enough: a $5.4-billion-a-quarter company that sells stents, valves, ablation catheters and left-atrial-appendage closure devices to hospitals that schedule procedures around delivery windows is, as of this writing, unable to promise delivery windows.

The industry has seen this movie once already this year. Stryker was hit on March 11. Its ordering, shipping and manufacturing systems went down for weeks and weren’t fully restored until the first week of April. When Q1 results came in, growth was 2.6% against a company that had posted 10% to 12% every quarter of the prior year. RBC estimated the miss at about $317 million in organic sales. CEO Kevin Lobo said some procedures were lost and some reps couldn’t get into hospitals, 40,000 laptops were wiped, and the company insisted no customers were. By the July call it was still working through an order backlog.

Stryker’s attack landed three weeks before quarter-end. Boston Scientific’s landed five weeks before its own. The arithmetic is not complicated.

It lands on a company that was already recalibrating. Boston Scientific cut its 2026 outlook in late July, trimming organic growth to 5%–6% from 6.5%–8% and adjusted EPS to $3.28–$3.32, after Watchman volumes came in soft as physicians bundled the implant into other procedures rather than scheduling it on its own. A restructuring program with $700 million to $800 million in charges was approved the same summer. Stifel’s note Wednesday was blunt about what the attack does to the model: “increased uncertainty regarding our 2026 revenue, margin, and EPS outlook,” with no clarity yet on how the company will quantify or communicate it.

Step back and the pattern is the story. Medical device makers went years without a meaningful operational cyber event. In 2026 alone, UFP Technologies, Stryker, Intuitive, Medtronic, iRhythm, AdaptHealth, Abbott, Cook Medical and Baylor Genetics have all disclosed incidents. Most were data breaches — employee records, customer contact lists, patient information — that the companies described as non-material to operations. Two were not. Two of the five largest pure-play device companies in the world have now had their order desks taken offline within six months of each other.

That changes the questions hospital procurement asks. Supply chain teams that spent 2022 and 2023 building dual-source plans for resins and semiconductors now have a second category of single point of failure to plan around, and it isn’t a factory. Expect resilience language — restoration SLAs, manual-ordering fallbacks, inventory buffers held at the customer — to start showing up in GPO negotiations the way cybersecurity attestations showed up in device labeling after the FDA’s 2023 premarket requirements.

For everyone below the top five, the lesson is sharper. Stryker and Boston Scientific will recover; they have the balance sheet, the backlog and the customer relationships to absorb a lost month. A commercial-stage company with one product, one ERP instance and a Q3 revenue target does not. The question is no longer whether your product can get through the FDA. It’s whether your revenue can survive three weeks without an order desk — and whether anyone in the building has actually rehearsed the answer.

Boston Scientific says it will post updates to its website. As of Thursday morning there were none.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.

8 things to watch this week:

1. 🏛️ Trump taps White House aide Heidi Overton to run the FDA

President Trump nominated Dr. Heidi Overton — deputy director of the White House Domestic Policy Council, former America First Policy Institute health chief, and the architect behind the administration’s vaccine-schedule and food-pyramid moves — to fill the commissioner seat vacant since Marty Makary resigned in May. Senate HELP chair Bill Cassidy, whose committee runs the confirmation, immediately voiced “strong concerns” about her lack of managerial experience; with MDUFA VI headed to Congress in January and the agency still absorbing staff cuts, the question of who’s actually running CDRH’s parent just got a longer runway.

RAPS

2. 🤖 FDA floats “competency assessment” model for generative-AI devices

The FDA’s Digital Health Center of Excellence published a discussion paper proposing a two-axis risk framework and a premarket approach modeled on how physicians are trained and evaluated — non-clinical benchmarking plus clinical confirmation — along with risk-proportionate postmarket monitoring and first agency thinking on foundation models and agentic AI. Comments are due October 19 under docket FDA-2026-N-7874; if a large language model is anywhere in your product roadmap, the premarket path is being drawn right now and the docket is where you draw it.

FDA

3. 🧭 Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you're strongest, where you're exposed, and what to fix first. If you want help closing a gap, it'll point you to the right starting place.

Take the Readiness Check →

Sponsored by RŌG Health

4. 🧠 ARPA-H hands Siemens Healthineers $31M to build an autonomous stroke robot

Siemens Healthineers will receive up to $31.1 million over five years — plus a $5.4 million cost share of its own — to develop endovascular robotics that perform mechanical thrombectomy remotely and without direct human input, with Stryker signed on as sub-awardee under the two companies’ 2025 neurovascular partnership. The agency’s math is the story: only about 12% of 335,000 eligible U.S. stroke patients get thrombectomy each year, and more than half the population lives over an hour from a center that can do it. Autonomy isn’t the goal; distribution is.

Radiology Business

5. ⚖️ Applied Medical asks court to permanently restrict Medtronic’s hospital contracts

Six months after a federal jury hit Medtronic with $382 million in damages for bundling LigaSure below cost and locking Applied’s Voyant out of GPO contracts, Applied has moved for a permanent injunction that would bar Medtronic from penalizing hospitals — through pricing, rebates or contract terms — for buying or even trialing a competitor’s vessel sealer. Applied says it turned down a Medtronic offer to carve out Applied alone; if the court agrees the remedy should open the market rather than protect one supplier, every strategic with a bundled-contract playbook has a new template to read.

MD+DI

6. 🏭 Intuitive plans 316,000-square-foot instrument plant in Malaysia

Intuitive signed a lease with Penang Development Corp. for a facility in Bandar Cassia Technology Park that will manufacture da Vinci instruments and electromechanical components starting in 2028, with 1,200 jobs targeted by 2032. The company framed it as Asia Pacific demand, which is true; it’s also a second instrument-manufacturing base for a company whose Mexicali plant has carried a lot of tariff exposure, and a signal of where the next wave of medtech capex is landing.

MassDevice

7. 💵 CMS grants add-on payment for Aidoc’s foundation-model CT triage

Aidoc’s CARE Body CT Multi-Triage — 14 cleared indications flagged from a single foundation model — will be eligible for a Medicare New Technology Add-on Payment on qualifying fee-for-service inpatient cases starting October 1, for three years. Aidoc calls it the first NTAP for a broad, multi-finding AI built on a foundation model rather than a single-condition algorithm; if that architecture is now reimbursable, the economics of building “one model, many indications” just changed for everyone behind them.

Diagnostic Imaging

8. 🔁 Haemonetics wins back CSL’s U.S. plasma business four years after losing it

Haemonetics disclosed in an SEC filing that CSL Plasma will begin transitioning some of its U.S. collection centers to the NexSys PCS platform, reversing a 2022 non-renewal that cost Haemonetics roughly an eighth of its revenue and sent CSL’s 300-plus centers to Terumo. The deal is non-exclusive with no minimums, but shares jumped about 15% and Needham sees a potential $183–223 million in annual revenue if the switch goes all the way. A reminder that a lost anchor account isn’t necessarily lost; NexSys’ Persona Plus clearance earlier this year appears to have been the reopening.

MassDevice

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.

The First Robot Licensed to Stick You.

The FDA did something on Tuesday that it has never done before: it authorized a machine to perform venipuncture on its own.

The device is the Aletta, built by Utrecht-based Vitestro, and the agency granted it marketing authorization through the De Novo pathway as the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention. A patient places their arm in the machine. The Aletta scans with near-infrared light and Doppler ultrasound to find a vein — and to confirm it isn’t an artery — then applies the tourniquet, preps the skin, inserts the needle, swaps collection tubes, and places the bandage. If it can’t find a suitable vein, it declines to try. If the patient moves too much, the needle detaches automatically and the draw stops.

A trained phlebotomist still initiates each session and supervises throughout. But here is the number that matters: one phlebotomist can oversee up to three Aletta devices at once. That ratio is the entire commercial thesis. Blood draws are among the most commonly performed procedures in American medicine, the phlebotomist shortage is real and worsening, and Vitestro is not selling a robot so much as selling a 3-to-1 conversion on scarce labor.

What should hold the attention of anyone who builds devices is how the FDA cleared it. The agency’s authorization rests on clinical data showing the Aletta achieves successful draw rates comparable to or better than trained human phlebotomists when it proceeds with a stick — demonstrated across patients with varying health statuses, self-reported difficult vein access, and varying skin tones. In pivotal testing, the device posted a 94.5% first-stick success rate, and 90% of patients reported pain equal to or less than a manual draw. The regulatory benchmark for an autonomous device, in other words, was the human it replaces. Expect that comparator design to become the template for every autonomous-care submission that follows.

The second structural detail is buried in the authorization itself. Alongside the De Novo, the FDA established special controls — labeling, performance, and clinical testing requirements that define a brand-new device category. Once those controls exist, competitors don’t need their own De Novo. They can reach the U.S. market through the 510(k) pathway, citing Aletta as the predicate class. Vitestro spent years and considerable capital being first; the reward is roughly a product cycle of runway before the door it opened admits everyone else. That is the standing bargain of the De Novo pathway, and this is as clean an example as the industry gets.

Vitestro appears to have priced that bargain in. The company raised $70 million in March expressly to fund the U.S. entry — a Series B whose investors include Labcorp Venture Fund, Mayo Clinic, and Sutter Health. Read that list again: a national reference lab and two major health systems, all of whom operate exactly the high-volume outpatient draw sites Vitestro says it will target first. The cap table is the distribution plan. The Aletta earned its CE mark in August 2024 and has been running in European hospitals since — meaning the U.S. launch arrives with operational evidence, not just trial data.

The Aletta will not take blood from your toughest stick, and it isn’t going into inpatient units yet — the authorization covers adults in outpatient settings, under supervision. But the categorical line it crossed doesn’t get uncrossed. The FDA has now written rules for machines that perform invasive procedures on their own, and it graded the first one against people.

SPONSORED BY RŌG HEALTH

Most device companies don't fail on technology. They fail on sequencing.

The free Commercial Readiness Check from RŌG Health takes two minutes and scores your commercialization across six dimensions — where you’re strongest, where you’re exposed, and what to fix first. If you want help closing a gap, it’ll point you to the right starting place.

Take the Readiness Check →

Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.

If this was useful, consider subscribing or sharing with a colleague tracking these developments.

Share The Pathway

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.